CN115925982A - Gdf15融合蛋白及其用途 - Google Patents
Gdf15融合蛋白及其用途 Download PDFInfo
- Publication number
- CN115925982A CN115925982A CN202211012820.3A CN202211012820A CN115925982A CN 115925982 A CN115925982 A CN 115925982A CN 202211012820 A CN202211012820 A CN 202211012820A CN 115925982 A CN115925982 A CN 115925982A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- fusion protein
- gdf15
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021109773787 | 2021-08-24 | ||
| CN202110977378 | 2021-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115925982A true CN115925982A (zh) | 2023-04-07 |
Family
ID=85321545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211012820.3A Pending CN115925982A (zh) | 2021-08-24 | 2022-08-23 | Gdf15融合蛋白及其用途 |
| CN202211013315.0A Pending CN115925984A (zh) | 2021-08-24 | 2022-08-23 | Gdf15融合蛋白及其用途 |
| CN202211012940.3A Pending CN115925983A (zh) | 2021-08-24 | 2022-08-23 | Gdf15融合蛋白及其用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211013315.0A Pending CN115925984A (zh) | 2021-08-24 | 2022-08-23 | Gdf15融合蛋白及其用途 |
| CN202211012940.3A Pending CN115925983A (zh) | 2021-08-24 | 2022-08-23 | Gdf15融合蛋白及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20240350588A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4393941A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532882A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240049337A (cg-RX-API-DMAC7.html) |
| CN (3) | CN115925982A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022333099A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226178A1 (cg-RX-API-DMAC7.html) |
| WO (3) | WO2023025120A1 (cg-RX-API-DMAC7.html) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101198698A (zh) * | 2005-03-31 | 2008-06-11 | 中外制药株式会社 | 通过调节缔合制备多肽的方法 |
| CN104204218A (zh) * | 2012-01-26 | 2014-12-10 | 安姆根有限公司 | 生长分化因子15 (gdf-15)多肽 |
| CN105980400A (zh) * | 2013-07-31 | 2016-09-28 | 美国安进公司 | 生长分化因子15(gdf-15)构建体 |
| CN111954537A (zh) * | 2018-04-09 | 2020-11-17 | 美国安进公司 | 生长分化因子15融合蛋白 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Fc領域を含むモノマーポリペプチド及び使用方法 |
| CN105102618B (zh) * | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| EP3027647A4 (en) * | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| SG10201913507SA (en) * | 2014-05-02 | 2020-02-27 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CN113286812B (zh) * | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20210080460A (ko) * | 2018-10-23 | 2021-06-30 | 드래곤플라이 쎄라퓨틱스, 인크. | 이종이량체성 Fc-융합된 단백질 |
| BR112021021271A2 (pt) * | 2019-04-23 | 2021-12-21 | Lg Chemical Ltd | Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15 |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| CA3161302A1 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| CA3171363A1 (en) * | 2019-12-20 | 2021-06-24 | Kisoji Biotechnology Inc. | Polypeptides, protein complexes and method for making same |
| EP4458863A1 (en) * | 2021-12-31 | 2024-11-06 | Sunshine Lake Pharma Co., Ltd. | Fusion protein of glp-1 and gdf15 and use thereof |
-
2022
- 2022-08-23 US US18/682,002 patent/US20240350588A1/en active Pending
- 2022-08-23 WO PCT/CN2022/114096 patent/WO2023025120A1/en not_active Ceased
- 2022-08-23 CN CN202211012820.3A patent/CN115925982A/zh active Pending
- 2022-08-23 US US18/685,702 patent/US20240391971A1/en active Pending
- 2022-08-23 KR KR1020247009488A patent/KR20240049337A/ko active Pending
- 2022-08-23 CN CN202211013315.0A patent/CN115925984A/zh active Pending
- 2022-08-23 US US18/294,397 patent/US20240343770A1/en active Pending
- 2022-08-23 CN CN202211012940.3A patent/CN115925983A/zh active Pending
- 2022-08-23 AU AU2022333099A patent/AU2022333099A1/en active Pending
- 2022-08-23 EP EP22860469.0A patent/EP4393941A4/en active Pending
- 2022-08-23 WO PCT/CN2022/114130 patent/WO2023025123A1/zh not_active Ceased
- 2022-08-23 CA CA3226178A patent/CA3226178A1/en active Pending
- 2022-08-23 EP EP22860466.6A patent/EP4392461A4/en active Pending
- 2022-08-23 WO PCT/CN2022/114143 patent/WO2023025129A1/zh not_active Ceased
- 2022-08-23 JP JP2024512156A patent/JP2024532882A/ja active Pending
- 2022-08-23 EP EP22860475.7A patent/EP4393940A4/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101198698A (zh) * | 2005-03-31 | 2008-06-11 | 中外制药株式会社 | 通过调节缔合制备多肽的方法 |
| CN104204218A (zh) * | 2012-01-26 | 2014-12-10 | 安姆根有限公司 | 生长分化因子15 (gdf-15)多肽 |
| CN105980400A (zh) * | 2013-07-31 | 2016-09-28 | 美国安进公司 | 生长分化因子15(gdf-15)构建体 |
| CN111954537A (zh) * | 2018-04-09 | 2020-11-17 | 美国安进公司 | 生长分化因子15融合蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240350588A1 (en) | 2024-10-24 |
| EP4393941A4 (en) | 2025-10-15 |
| AU2022333099A1 (en) | 2024-02-08 |
| KR20240049337A (ko) | 2024-04-16 |
| CA3226178A1 (en) | 2023-03-02 |
| EP4393941A1 (en) | 2024-07-03 |
| WO2023025120A1 (en) | 2023-03-02 |
| JP2024532882A (ja) | 2024-09-10 |
| CN115925983A (zh) | 2023-04-07 |
| CN115925984A (zh) | 2023-04-07 |
| EP4393940A1 (en) | 2024-07-03 |
| WO2023025129A1 (zh) | 2023-03-02 |
| EP4392461A4 (en) | 2025-10-15 |
| EP4393940A4 (en) | 2025-10-15 |
| US20240391971A1 (en) | 2024-11-28 |
| EP4392461A1 (en) | 2024-07-03 |
| WO2023025123A1 (zh) | 2023-03-02 |
| US20240343770A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250084144A1 (en) | Dual-target fusion proteins comprising fgf21 and glp-1, connected through a fc portion of an immunoglobulin | |
| JP6182600B2 (ja) | 線維芽細胞増殖因子21タンパク質 | |
| KR102217254B1 (ko) | 대사 장애를 치료하기 위한 이중 기능 단백질 | |
| CN113292646B (zh) | Glp-1/胰高血糖素双重激动剂融合蛋白 | |
| CN114591415B (zh) | Glp-1/gcg双受体激动剂多肽及其融合蛋白 | |
| CA3096097A1 (en) | Growth differentiation factor 15 fusion proteins | |
| CN106432509A (zh) | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 | |
| TWI889865B (zh) | 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途 | |
| WO2023280133A1 (zh) | 融合蛋白及其应用 | |
| US20250179142A1 (en) | Fusion protein of glp-1 and gdf15 and use thereof | |
| CN116096396A (zh) | 由于异位骨化的副作用减少而具有增强的治疗效果的骨形态发生蛋白-9和骨形态发生蛋白-10变体以及包含所述变体的药物组合物 | |
| WO2023025120A1 (en) | Gdf15 fusion proteins and uses thereof | |
| CN116948037A (zh) | 一种新结构长效卵泡刺激素重组蛋白及其制备和应用 | |
| CA2469724A1 (en) | Mutant glycoproteins | |
| US20090270325A1 (en) | Growth factor | |
| HK1045160A (en) | Expression and export of anti-obesity proteins as fc fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Applicant after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |